X

Trial Profile

A Single-arm, Prospective, Multi-center Study of Nucel in Patients Receiving Interbody Fusion for One and Two Level Degenerative Disease of the Lumbar Spine

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 May 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amniotic cell therapy-NuCel (Primary)
Indications Intervertebral disc degeneration; Spinal disorders; Spondylolisthesis; Spondylosis
Focus Therapeutic Use
Sponsors Organogenesis

Most Recent Events

21 May 2021 Status changed from recruiting to active, no longer recruiting.
15 May 2019 Planned End Date changed from 1 Feb 2020 to 1 Dec 2022.
15 May 2019 Planned primary completion date changed from 1 Feb 2020 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com